Kendle Announces Acquisition of Phase II-IV Clinical Services Business of Charles River Laboratories International, Inc.
May 09 2006 - 10:30PM
PR Newswire (US)
- Advances Company's competitive position to world's fourth largest
provider of Phase II-IV clinical services CINCINNATI, May 9
/PRNewswire-FirstCall/ -- Kendle (NASDAQ:KNDL), a leading global
full-service clinical research organization (CRO), today announced
the signing of a definitive agreement to acquire the Phase II-IV
Clinical Services business of Charles River Laboratories
International, Inc. (NYSE:CRL) creating the world's fourth largest
provider of Phase II-IV clinical development services. With this
move, Kendle strengthens its position as one of the leading global
players in the clinical development industry, adding attractive
therapeutic expertise, diversifying its customer base and expanding
its capacity to deliver global trials. The transaction is expected
to close in the third quarter of 2006, subject to customary closing
conditions and regulatory approvals. The company will host a
conference call and Webcast Wednesday, May 10, 2006, at 11:30 a.m.
Eastern Time to discuss the acquisition (see below for details).
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO ) "We
are excited by this move, which is an important component of our
overall growth strategy designed to significantly enhance our
global competitive position and accelerate Kendle to a $500 million
organization," said Candace Kendle, PharmD, Chairman and Chief
Executive Officer. "Our customers will benefit from our
strengthened global project leadership capability, expanded
therapeutic expertise in the fastest-growing areas of clinical
development and enhanced depth in North America and a number of key
European markets. We look forward to completing the integration of
our new operations into Kendle under our four service brands, and
adding value for our customers through our combined organization."
The acquisition adds approximately $103 million in unaudited net
service revenues to Kendle's 2005 performance, representing
significant growth relative to 2005 actual results and putting
Kendle ahead of its long-term strategic plan to outperform the
market as a leading global CRO. The strategic combination will
offer biopharmaceutical customers the benefit of a broadened
therapeutic base, stronger global footprint and an expanded depth
of global clinical development services. The move also strengthens
the company's global project leadership expertise, which has been a
cornerstone of its growth and success. The acquired operations will
operate under the Kendle name. The acquisition provides Kendle with
a broadened strategic platform for growth to capitalize on the
increasing demand for global clinical development services. The
acquired assets bring the following key attributes to the expanded
Kendle: * Strong and growing backlog * Therapeutic expertise in
high-value categories such as oncology, infectious disease,
respiratory, cardiovascular and ophthalmology * Attractive customer
base providing very little overlap with Kendle's existing customers
* Skilled and experienced workforce with significant therapeutic
and global project leadership expertise, providing increased
capacity to deliver global trials The agreement provides for the
purchase of 100 percent of the stock of the Phase II-IV Clinical
Services business for approximately $215 million in cash. This
amount is subject to working capital adjustments to be determined
at closing. Kendle intends to finance the transaction with a
combination of cash on hand and debt. Kendle has obtained a
commitment for financing necessary to complete the acquisition from
UBS Investment Bank, which is also acting as Kendle's exclusive
financial advisor in connection with the transaction. Investor
Conference Call and Webcast Kendle will host a telephone conference
call and Webcast to discuss the acquisition on Wednesday, May 10,
at 11:30 a.m. Eastern Time. Conference Call Details Dial-in:
800-399-0069 (United States and Canada) 706-643-3694 (Outside North
America) Replay: 706-645-9291 Conference ID Number 9068977 Webcast
Please go to http://www.kendle.com/ or
http://www.videonewswire.com/event.asp?id=33899 . The Webcast will
be archived at http://www.kendle.com/ (click on "Investors")
shortly after the call. The conference call and archived Webcast
will be available until 5 p.m. Eastern Time on Friday, June 9.
About Kendle Kendle International Inc. (NASDAQ:KNDL) is among the
world's leading global clinical research organizations. We deliver
innovative and robust clinical development solutions -- from
first-in-human studies through market launch and surveillance -- to
help the world's biopharmaceutical companies maximize product life
cycles and grow market share. Our global clinical development
business is focused on five regions - North America, Europe,
Asia/Pacific, Latin America and Africa - to meet customer needs.
With the expertise of our associates worldwide, Kendle has
conducted clinical trials or provided regulatory, pharmacovigilance
and validation services in 70 countries. Additional information and
investor kits are available upon request from Kendle, 1200 Carew
Tower, 441 Vine Street, Cincinnati, OH 45202 or from the Company's
Web site at http://www.kendle.com/. Information provided herein,
which is not historical information, such as statements about
accelerating the Company's efforts to grow to a $500 million
organization, broadening our strategic platform for growth,
enhancing our global competitive position, are forward-looking
statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such forward-looking
statements, are based largely on management's expectations and are
subject to and qualified by risks and uncertainties that could
cause actual results and events currently expected by the Company
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include, without
limitation, the acquisition may not be consummated by the expected
closing or at all, receipt of regulatory approval and financing
without unexpected delays, timely implementations and execution of
integration plans, the acquisition may involve unexpected costs,
the combined company may be unable to achieve cost-cutting
synergies, the businesses may suffer as a result of uncertainty
surrounding the acquisition, the Company's ability to manage growth
and to continue to attract and retain qualified personnel, the
Company's ability to complete additional acquisitions and to
integrate newly acquired businesses, cancellation or delay of
contracts, ability to maintain existing customer relationships or
enter into new ones, the economic climate nationally and
internationally as it affects the drug development operations and
other factors beyond the control of the Company described in the
Company's filings with the Securities and Exchange Commission
including Quarterly Reports on Form 10-Q and the Annual Report on
Form 10-K. All information in this release is current as of May 9,
2006. The Company undertakes no duty to update any forward-looking
statement to conform the statement to actual results or changes in
the Company's expectations.
http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO
http://photoarchive.ap.org/ DATASOURCE: Kendle CONTACT: Patty
Frank, Investors, +1-513-763-1992, Lori Dorer, Media,
+1-513-345-1685, both of Kendle Web site: http://www.kendle.com/
Copyright
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jul 2023 to Jul 2024